EMBARGOED UNTIL 9:30 A.M. CT, April 5, 2011 ACC i2 Poster Contributions Session No. 2516 (Poster #507) WHAT: Principal Investigator Dr. Raymond Dattilo, St. Francis Health Center, Topeka, Kan., will present preliminary acute results of the COMPLIANCE 360° study. The COMPLIANCE 360° is a prospective, randomized multicenter feasibility study that examines whether the Diamondback 360º PAD System, by improving lesion compliance through differential sanding, can achieve satisfactory acute and durable results without the need for stent placement. In the COMPLIANCE 360° study, 50 patients were enrolled at nine U.S. sites. The Diamondback 360º PAD System is a minimally invasive orbital atherectomy system indicated for use as therapy in patients with peripheral arterial disease (PAD) – blockages in leg arteries. WHEN: Tuesday, April 5, 9:30 a.m. – 10:45 a.m. WHERE: Hall F, Ernest N. Morial Convention Center, 900 Convention Center Blvd., New Orleans THE CV Innovations Educational Forum WHAT: Drs. Stevan Himmelstein, Baptist Memorial Hospital-Desoto, Memphis, Tenn., and Jeffrey Chambers, Mercy Hospital, Minneapolis will provide an overview of their use of the Diamondback 360° at the ACC CV Innovations Forum, which features cutting-edge research and product development. They will discuss their clinical experience with CSI’s orbital technology for peripheral and coronary applications, along with highlights of CSI’s clinical data with an emphasis on small, calcified vessels. WHEN: Monday, April 4:
- 9:45 a.m.: Advancing the Standard of Care for Treating PAD, Dr. Himmelstein
- 10 a.m.: The Future of Coronary Interventions, Dr. Chambers
INTERVIEW OPPORTUNITIES: Interviews can be requested by contacting Nancy Johnson, (612) 455-1745 (o), (612) 812-7568 (c) email@example.com, or Nick Banovetz (612) 455-1705 (o) or (651) 815-5999 (c), Padilla Speer Beardsley.About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing interventional treatment systems for vascular disease. For more information visit the company’s Web site at www.csi360.com.